High Prevalence of Hyperglycaemia and Dyslipidaemia in Zimbabwean Adults on Therapy
A recent study has highlighted significant health concerns for adults living with HIV in Zimbabwe who are undergoing treatment with dolutegravir (DTG)-based antiretroviral therapy (ART). The research, conducted between January and February 2025, involved 171 participants at the Parirenyatwa Group of Hospitals in Harare. The study aimed to estimate the prevalence of hyperglycaemia and dyslipidaemia among these individuals and identify associated risk factors. Findings revealed that 74.3% of participants experienced dyslipidaemia, while 13.4% were affected by hyperglycaemia. Notably, insulin resistance was present in 56.1% of the cohort. The study's demographic data indicated that the majority of participants were female, with a median age of 42.1 years. Many reported lifestyle factors such as low physical activity and high rates of overweight or obesity, with 57.9% classified as overweight or obese and 39.8% hypertensive. The research underscores the importance of integrated health monitoring for this population, particularly as they age and continue long-term ART. The study advocates for routine screening of body mass index (BMI), blood pressure, glucose, and lipid profiles to address the heightened risk of cardiovascular disease and type 2 diabetes associated with these metabolic abnormalities. This research is crucial as it provides local data to inform healthcare strategies aimed at improving the quality of care for individuals living with HIV in Zimbabwe.




